|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang S, Wu K, Feng J, Wu Z, Deng Q, Guo
C, Xia B, Zhang J, Huang H, Zhu L, et al: Epigenetic therapy
potential of suberoylanilide hydroxamic acid on invasive human
non-small cell lung cancer cells. Oncotarget. 7:68768–68780. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) methods. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243–6249. 2006. View Article : Google Scholar
|
|
5
|
Omuro AM, Kris MG, Miller VA, Franceschi
E, Shah N, Milton DT and Abrey LE: High incidence of disease
recurrence in the brain and leptomeninges in patients with
non-small cell lung carcinoma after response to gefitinib. Cancer.
103:2344–2348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW,
Park IK, Kim JH and Cho BC: Frequent central nervous system failure
after clinical benefit with epidermal growth factor receptor
tyrosine kinase inhibitors in Korean patients with non small-cell
lung cancer. Cancer. 116:1336–1343. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cirillo LA and Zaret KS: An early
developmental transcription factor complex that is more stable on
nucleosome core particles than on free DNA. Mol Cell. 4:961–969.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zaret K: Developmental competence of the
gut endoderm: Genetic potentiation by GATA and HNF3/fork head
proteins. Dev Biol. 209:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cirillo LA, Lin FR, Cuesta I, Friedman D,
Jarnik M and Zaret KS: Opening of compacted chromatin by early
developmental transcription factors HNF3 (FoxA) and GATA-4. Mol
Cell. 9:279–289. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carroll JS, Liu XS, Brodsky AS, Li W,
Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger
TR, et al: Chromosome-wide mapping of estrogen receptor binding
reveals long-range regulation requiring the forkhead protein FoxA1.
Cell. 122:33–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Laganiere J, Deblois G, Lefebvre C,
Bataille AR, Robert F and Giguere V: From the cover: Location
analysis of estrogen receptor alpha target promoters reveals that
FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci
USA. 102:11651–11656. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Albergaria A, Paredes J, Sousa B, Milanezi
F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, et al:
Expression of FOXA1 and GATA-3 in breast cancer: The prognostic
significance in hormone receptor-negative tumors. Breast Cancer
Res. 11:R402009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abe Y, Ijichi N, Ikeda K, Kayano H,
Horie-Inoue K, Takeda S and Inoue S: Forkhead box transcription
factor, forkhead box A1, shows negative association with lymph
nodes status in endometrial cancer, and represses cell
proliferation and migration of endometrial cancer cells. Cancer
Sci. 103:806–812. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sahu B, Laakso M, Ovaska K, Mirtti T,
Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, et
al: Dual role of FOXA1 in androgen receptor binding to chromatin,
androgen signaling and prostate cancer. EMBO J. 30:3962–3976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song Y, Washington MK and Crawford HC:
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal
transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin L, Miller CT, Contreras JI, Prescott
MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, et
al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1),
on chromosome band 14q13 is amplified and overexpressed in
esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279.
2002.PubMed/NCBI
|
|
17
|
Ma W, Jiang J, Li M, Wang H, Zhang H, He
X, Huang L and Zhou Q: The clinical significance of forkhead box
protein A1 and its role in colorectal cancer. Mol Med Rep.
14:2625–2631. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nucera C, Eeckhoute J, Finn S, Carroll JS,
Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al:
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin
Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deutsch L, Wrage M, Koops S, Glatzel M,
Uzunoglu FG, Kutup A, Hinsch A, Sauter G, Izbicki JR, Pantel K and
Wikman H: Opposite roles of FOXA1 and NKX2-1 in lung cancer
progression. Gene Chromosome Canc. 51:618–629. 2012. View Article : Google Scholar
|
|
20
|
Wang H, Meyer CA, Fei T, Wang G, Zhang F
and Liu XS: A systematic approach identifies FOXA1 as a key factor
in the loss of epithelial traits during the
epithelial-to-mesenchymal transition in lung cancer. BMC Genomics.
14:6802013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan
S, Cai H, Luo Q, Lv Z and Fan L: miR-194 inhibits the
proliferation, invasion, migration, and enhances the
chemosensitivity of non-small cell lung cancer cells by targeting
forkhead box A1 protein. Oncotarget. 7:13139–13152. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang R, Shi Y, Chen L, Jiang Y, Mao C, Yan
B, Liu S, Shan B, Tao Y and Wang X: The ratio of FOXA1 to FOXA2 in
lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin
remodeling factor LSH. Sci Rep. 5:178262015. View Article : Google Scholar : PubMed/NCBI
|
